DJO Global said this week that it hired Jeffery McCaully as global president of its surgical business, effectively immediately. McCaulley succeeded Brady Shirley, who was named DJO’s president & CEO in November last year. McCaulley previously served as president & CEO of Smiths Medical, as well as president of Zimmer Biomet‘s (NYSE:ZBH) global reconstructive unit, where […]
Royal Philips (NYSE:PHG) has promoted its India managing director and CEO Krishna Kumar to a position managing its emerging healthcare business division, according to The Times of India. Kumar is slated to continue as managing director of Philips India division until December, at which point he will lead the development of consumer and profesisonal healthcare […]
The market for hip and knee implants is stable but mired in a low-growth stage, according to analysts who attended the American Academy of Orthopedic Surgeons conference in San Francisco last week.
Although the abrupt departure of Stryker CEO Steve MacMillan drew the lion’s share of attention at the AAOS event, analysts from Barclays Capital and Leerink Swann agreed that the sector’s outlook calls for low-single-digit growth.
Rather than wage a legal battle against the SEC, Daxor Corp. (NYSE:DXR) plans to register as an investment company, as ordered by an administrative law judge for the watchdog agency.
Daxor said it made the decision not to appeal the initial SEC decision so that it can focus on research & development for its blood volume analyzer, rather than incurring the risk and cost of a legal battle or taking the company private.
NEW YORK, NY–(Marketwire – Nov 18, 2011) – Daxor Corporation (NYSE Amex: DXR)
In our press release of September 1, 2011, the Company disclosed that on August 31, 2011, an Administrative Law Judge of the Securities and Exchange Commission issued an Initial Decision finding that Daxor is an investment company within the meaning of the Investment Company Act of 1940….
Zoll reported record numbers in its top and bottom line for fiscal year 2011, sending its stock up 23 percent overnight.
Zoll shares were trading at $44.35 in the early afternoon today, up from last night’s $35.98 close.
The company’s 2011 sales hit a record high of $523.7 million, 18 percent higher than the $444 million posted last year.